TY - JOUR T1 - Retrospective single centre review of solid-organ malignancy post-lung transplant JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA1109 VL - 54 IS - suppl 63 SP - PA1109 AU - Colin Rutherford AU - S Winward AU - I Lawrie AU - S Towell AU - P Ging AU - J Kleinerova AU - J Egan Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA1109.abstract N2 - Introduction: An increased risk of malignancy post-lung transplant (LTx) is established as a complication related to reduced immunosurveillance and patient demographics.Aims: To identify the incidence, risk factors and clinical characteristics of solid-organ malignancy following LTx at The Irish National Lung Transplant Centre.Methods: A retrospective single centre review of all 216 patients transplanted between 2005-2017. Data collected included patient demographics, transplant indication, surgery, smoking status, histological sub-type, TNM staging and outcomes.Results: Nineteen patients were diagnosed with a solid-organ malignancy following LTx during follow-up (8.8%). The median time interval between transplant and cancer diagnosis was 32 months (range 12-133 months). Age at the time of transplant was significantly higher in those who subsequently developed malignancy (p=0.028, mean 58.3 v 49.7 years). Single LTx recipients appear at higher risk compared to double LTx recipients (OR 3.17, 95% CI 1.10-9.14). No single indication for LTx was identified as an independent risk factor.Bronchogenic carcinoma was the most common malignancy (n=11, 5.1%); the majority were identified in the native lung of single transplant recipients (9 of 11). 82% were ex-smokers. Squamous cell carcinoma was the most common subtype (n=5). Five patients were stage IV at diagnosis with an overall 1-year mortality of 82%.Conclusions: Bronchogenic carcinoma is the most common solid organ malignancy post LTx and has a high mortality. Risk factors include older age and single LTx. Despite close prospective monitoring, early detection remains challenging and adequate adequate screening guidelines post-transplant are currently lacking.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1109.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -